1. Home
  2. BTAI vs GV Comparison

BTAI vs GV Comparison

Compare BTAI & GV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTAI
  • GV
  • Stock Information
  • Founded
  • BTAI 2017
  • GV 2013
  • Country
  • BTAI United States
  • GV Canada
  • Employees
  • BTAI N/A
  • GV N/A
  • Industry
  • BTAI Biotechnology: Pharmaceutical Preparations
  • GV Other Consumer Services
  • Sector
  • BTAI Health Care
  • GV Real Estate
  • Exchange
  • BTAI Nasdaq
  • GV Nasdaq
  • Market Cap
  • BTAI 8.3M
  • GV 7.8M
  • IPO Year
  • BTAI 2018
  • GV 2022
  • Fundamental
  • Price
  • BTAI $1.84
  • GV $1.77
  • Analyst Decision
  • BTAI Buy
  • GV
  • Analyst Count
  • BTAI 5
  • GV 0
  • Target Price
  • BTAI $34.60
  • GV N/A
  • AVG Volume (30 Days)
  • BTAI 294.8K
  • GV 33.6K
  • Earning Date
  • BTAI 08-05-2025
  • GV 08-14-2025
  • Dividend Yield
  • BTAI N/A
  • GV N/A
  • EPS Growth
  • BTAI N/A
  • GV N/A
  • EPS
  • BTAI N/A
  • GV N/A
  • Revenue
  • BTAI $1,852,000.00
  • GV $7,773,905.00
  • Revenue This Year
  • BTAI $5.03
  • GV N/A
  • Revenue Next Year
  • BTAI $291.01
  • GV N/A
  • P/E Ratio
  • BTAI N/A
  • GV N/A
  • Revenue Growth
  • BTAI 5.47
  • GV N/A
  • 52 Week Low
  • BTAI $1.17
  • GV $1.00
  • 52 Week High
  • BTAI $23.04
  • GV $9.60
  • Technical
  • Relative Strength Index (RSI)
  • BTAI 62.90
  • GV 41.00
  • Support Level
  • BTAI $1.59
  • GV $1.72
  • Resistance Level
  • BTAI $2.22
  • GV $1.90
  • Average True Range (ATR)
  • BTAI 0.21
  • GV 0.11
  • MACD
  • BTAI 0.04
  • GV -0.01
  • Stochastic Oscillator
  • BTAI 75.00
  • GV 12.50

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About GV Visionary Education Technology Holdings Group Inc.

Visionary Holdings Inc is a private education providing company located in Canada, with subsidiaries in Canada and market partners in China, that offers high-quality education resources to students around the globe. The company aims to provide access to secondary, college, undergraduate and graduate, and vocational education to students in Canada through technological innovation so that more people can learn, grow, and succeed to their full potential. As a fully integrated provider of educational programs and services in Canada, the company has been serving and will continue to serve both Canadian and international students.

Share on Social Networks: